Galectin Therapeutics Inc.
Price Action
Technical Summary
WEAKENINGGalectin Therapeutics Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is leading (RS Rating: 91), indicating clear outperformance against the broad market. Earnings growth of 49% provides fundamental context to the price action. However, price is extended 66% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.28 | +37.62% | ABOVE |
| 50 SMA | $2.72 | +66.02% | ABOVE |
| 100 SMA | $2.75 | +63.74% | ABOVE |
| 150 SMA | $3.26 | +38.48% | ABOVE |
| 200 SMA | $3.71 | +21.47% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is GALT in an uptrend right now?
GALT has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is GALT overbought or oversold?
GALT's RSI (14) is 69. The stock is in neutral territory, neither overbought nor oversold.
Is GALT outperforming the market?
GALT has a Relative Strength (RS) Rating of 91 out of 99. Yes, GALT is a market leader, outperforming 91% of all stocks over the past 12 months.
Where is GALT in its 52-week range?
GALT is trading at $4.51, which is 63% of its 52-week high ($7.13) and 49% above its 52-week low ($2.02).
How volatile is GALT?
GALT has a Beta of 1.00 and 52-week volatility of 91%. It's less volatile than the S&P 500 - generally more stable.